Key takeaways from ISPOR Europe 2023
ISPOR Europe was the busiest we’ve ever seen it. Those few days were jam-packed with engaging plenary sessions, educational symposia, poster research, and networking opportunities. Many fruitful conversations were had, with the team contributing the following rundown...
The power of trial interviews
In October 2023, the US Food and Drug Administration (FDA) released their industry guidance for benefit-risk assessment of novel products¹, in which the role of patient experience data was highlighted in its capacity to “inform nearly every aspect of FDA’s...
Why your immunology portfolio needs a patient-centered real-world study
Patient-centered real-world research should be an essential part of the evidence development strategy for an immunology portfolio. Here, we discuss how this type of research can add particular value in autoimmune and immune-mediated diseases. Accurate measurement of...
Designing patient-centered registries to support regulatory decision-making
According to the FDA, a registry can be defined as “an organized system that collects clinical and other data in a standardized format for a population defined by a particular disease, condition, or exposure”1. Disease registries can be useful ways to: understand the...
